

World Journal of *Gastrointestinal Pharmacology and Therapeutics*

World J Gastrointest Pharmacol Ther 2017 August 6; 8(3): 155-192



Contents

Quarterly Volume 8 Number 3 August 6, 2017

EDITORIAL

- 155 Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature

Kothari MM, Nguyen DL, Parekh NK

REVIEW

- 162 Phage therapy: An alternative to antibiotics in the age of multi-drug resistance

Lin DM, Koskella B, Lin HC

MINIREVIEWS

- 174 Critically ill patients and gut motility: Are we addressing it?

Vazquez-Sandoval A, Ghamande S, Surani S

ORIGINAL ARTICLE**Retrospective Study**

- 180 Use of proton pump inhibitors in general practice

Tosetti C, Nanni I

Observational Study

- 186 Transition care in inflammatory bowel disease: A needs assessment survey of Quebec gastroenterologists and allied nurses

Strohl M, Zhang X, Lévesque D, Bessissow T

Contents

World Journal of Gastrointestinal Pharmacology and Therapeutics

Volume 8 Number 3 August 6, 2017

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Pharmacology and Therapeutics*, Bronislaw L Slomiany, DPhil, Professor, Research Center, C-875 Rutgers School of Dental Medicine, the State University of New Jersey, Newark, NJ 07103-2400, United States

AIM AND SCOPE

World Journal of Gastrointestinal Pharmacology and Therapeutics (World J Gastrointest Pharmacol Ther, WJGPT, online ISSN 2150-5349, DOI: 10.4292), is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJGPT covers topics concerning: (1) Clinical pharmacological research articles on specific drugs, concerning with pharmacodynamics, pharmacokinetics, toxicology, clinical trial, drug reactions, drug metabolism and adverse reaction monitoring, *etc.*; (2) Research progress of clinical pharmacology; (3) Introduction and evaluation of new drugs; (4) Experiences and problems in applied therapeutics; (5) Research and introductions of methodology in clinical pharmacology; and (6) Guidelines of clinical trial.

We encourage authors to submit their manuscripts to *WJGPT*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ABSTRACTING

World Journal of Gastrointestinal Pharmacology and Therapeutics is now indexed in PubMed, PubMed Central.

FLYLEAF

I-IV Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Ya-Jing Lu*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Fang-Fang Ji*
Proofing Editorial Office Director: *Ze-Mao Gong*

NAME OF JOURNAL

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

ISSN 2150-5349 (online)

LAUNCH DATE

May 6, 2010

FREQUENCY

Quarterly

EDITOR-IN-CHIEF

Hugh J Freeman, MD, FRCPC, FACP, Professor, Department of Medicine (Gastroenterology), University of British Columbia, Hospital, 2211 Wesbrook Mall, Vancouver, BC V6T1W5, Canada

EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjgnet.com/2150-5349/editorialboard.htm>

EDITORIAL OFFICE

Xiu-Xia Song, Director
World Journal of Gastrointestinal Pharmacology and Therapeutics
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER

Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLICATION DATE

August 6, 2017

COPYRIGHT

© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

<http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION

<http://www.f6publishing.com>

Phage therapy: An alternative to antibiotics in the age of multi-drug resistance

Derek M Lin, Britt Koskella, Henry C Lin

Derek M Lin, Henry C Lin, Section of Gastroenterology, New Mexico VA Health Care System, Albuquerque, NM 87108, United States

Britt Koskella, Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94720, United States

Henry C Lin, Department of Medicine, University of New Mexico, Albuquerque, NM 87131, United States

Author contributions: All authors contributed equally to this work with regard to the scope of the subject, the literature review and analysis, drafting, revision, editing, and final approval of the manuscript.

Supported by Winkler Bacterial Overgrowth Research Fund (in part).

Conflict-of-interest statement: No potential conflicts of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Henry C Lin, MD, Section of Gastroenterology, New Mexico VA Health Care System, 1501 San Pedro SE, Albuquerque, NM 87108, United States. helin@salud.unm.edu
Telephone: +1-505-2561711-4552

Received: November 2, 2016

Peer-review started: November 4, 2016

First decision: December 15, 2016

Revised: May 13, 2017

Accepted: May 30, 2017

Article in press: May 31, 2017

Published online: August 6, 2017

Abstract

The practice of phage therapy, which uses bacterial viruses (phages) to treat bacterial infections, has been around for almost a century. The universal decline in the effectiveness of antibiotics has generated renewed interest in revisiting this practice. Conventionally, phage therapy relies on the use of naturally-occurring phages to infect and lyse bacteria at the site of infection. Biotechnological advances have further expanded the repertoire of potential phage therapeutics to include novel strategies using bioengineered phages and purified phage lytic proteins. Current research on the use of phages and their lytic proteins against multidrug-resistant bacterial infections, suggests phage therapy has the potential to be used as either an alternative or a supplement to antibiotic treatments. Antibacterial therapies, whether phage- or antibiotic-based, each have relative advantages and disadvantages; accordingly, many considerations must be taken into account when designing novel therapeutic approaches for preventing and treating bacterial infection. Although much about phages and human health is still being discovered, the time to take phage therapy serious again seems to be rapidly approaching.

Key words: Bacteriophage; Bacteriophage therapy; Phage; Phage therapy; Endolysin; Lysin; Multidrug resistance; Antibiotic resistance; Phage safety; Methicillin-resistant *S. aureus*

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Phage therapy is widely being reconsidered as an alternative to antibiotics. The use of naturally-occurring phages to treat bacterial infection has a contentious history in western medicine. However, the emergent landscape of phage-based antimicrobials has advanced well beyond traditional methods. In this rapidly evolving field, novel technologies such as bioengineered chimeras of phage-derived lytic proteins show potential as a new class of antibacterial pharmaceuticals. This review aims to

provide a topical perspective on the historical context of phage therapy, in order to highlight modern advances in phage research and innovations in the field.

Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. *World J Gastrointest Pharmacol Ther* 2017; 8(3): 162-173 Available from: URL: <http://www.wjgnet.com/2150-5349/full/v8/i3/162.htm> DOI: <http://dx.doi.org/10.4292/wjgpt.v8.i3.162>

INTRODUCTION

Almost a decade before the discovery of penicillin, the controversial practice of phage therapy was being developed as a treatment for bacterial infections. Phages, short for bacteriophages, are bacteria-specific viruses that have been used as a treatment against pathogens such as *Shigella dysenteriae* as early as 1919^[1]. With an estimated 10^{31} - 10^{32} phages in the world at any given time^[2], they make up the most abundant biological entity on Earth and play a crucial role in regulating bacterial populations; phages are responsible for the death of approximately 20%-40% of all marine surface bacteria every 24 h^[3]. Much of the controversy surrounding phage therapy was due to poor documentation of use and variable success. The complications in implementing phage therapy stemmed from how little was known about phages at the time of their discovery. In fact, the nature of their existence was a topic of contention until they were visualized in the 1940's after the invention of electron microscopy^[4]. A number of logistical and technical obstacles in developing phage therapy led to its widespread abandonment after the discovery of antibiotics.

The advent of pharmaceutical antibiotics in the mid-20th century, along with a better understanding of disease and sanitation, revolutionized healthcare and drastically improved both quality of life and life expectancy in the industrialized world. In 1900, life expectancy for men and women in the United States was 46 and 48, respectively, and the major causes of death were infectious diseases, many of which were bacterial (e.g., cholera, diphtheria, typhoid fever, plague, tuberculosis, typhus, scarlet fever, pertussis, and syphilis)^[5]. Antibiotics helped usher in a new era in medicine, rapidly becoming an indispensable medical tool with 262.5 million treatment courses prescribed in the United States in 2011 alone (842 prescriptions per 1000 persons) and an estimated 100000-200000 tons of antibiotics used globally between medicine, agriculture, and horticulture each year^[6,7]. Antibiotic resistance genes encoding for bacterial resistance to common antibiotics, including β -lactams, aminoglycosides, chloramphenicols, and tetracycline, are posing a major threat to current medical treatment of common diseases, and these genes now appear

to be abundant in the environment^[8]. The spread of antibiotic resistance genes carries a unique danger in that many antibiotics have diminishing efficacy against common infections, particularly the difficult-to-treat nosocomial infections caused by the ESKAPE pathogens (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* spp.).

Admonitions of a return to "the pre-antibiotic era" have become increasingly common and regulatory organizations such as the Centers for Disease Control (CDC) and WHO have declared antibiotic resistance a threat to global health^[9,10]. The CDC estimates antibiotic-resistant infections result in 2 million illnesses and at least 23000 deaths a year, with many more dying from conditions complicated by antibiotic-resistant infections, costing the United States \$55 billion annually^[7]. According to the United Kingdom government's 2016 Review on Antimicrobial Resistance, an estimated 700000 people die each year globally from resistant infections with a projected cost of \$100 trillion and a death toll of 10 million by 2050^[7]. In the United States, methicillin-resistant *S. aureus* (MRSA) infections alone account for more deaths than HIV/AIDS and tuberculosis combined^[11]. Since the discovery of antibiotics, there has been a steady stream of novel antibacterial pharmaceuticals in what has been dubbed the "antibiotic pipeline". However, due to the rate at which bacteria evolve resistance to antibiotics, there has been less commercial interest in the research and development of novel compounds. In the years of 1983-1987, there were 16 new pharmaceutical antibiotics approved by the Food and Drug Administration (FDA) for use in the United States, this number has steadily trended downwards and between 2010-2016 only 6 new antibiotics were approved^[12]. At the end of the antibiotic pipeline is the carbapenem class of antibiotics, often reserved as the "last resort" due to their adverse effects on health. Beginning in 2000, the incidence of carbapenem-resistant, hospital-acquired *K. pneumoniae* infections began to increase in the United States; due to the lack of treatment options these infections are associated with a 40%-50% mortality rate^[13]. Reaching the end of the antibiotic pipeline could signal a shift in the global culture of infectious disease treatment and some claim is the imminent return to a pre-antibiotic era of medicine.

On September 21, 2016, the United Nations General Assembly convened to discuss the problem of antibiotic resistance and deemed it "the greatest and most urgent global risk"^[14]. In the hunt for alternative strategies for prophylaxis and control of bacterial infection, one of the more popular suggestions involves revisiting the practice of phage therapy. Proponents of phage therapy tout several major advantages that phages have over antibiotics such as host-specificity, self-amplification, biofilm degradation, and low toxicity to humans^[15,16]. Owing to the development of analytical tools capable of studying these small biological entities

(approximately 25-200 nm in length), such as next-generation sequencing and electron microscopy, the field of phage biology is only now reaching maturity. These technological advancements have ushered in a renaissance of phage therapy research as indicated by a wave of recent human clinical trials and animal research. The complex story of the human phageome in regards to health and disease is only beginning to unfold and will not be included in this review (for current literature review see Wahida, Ritter and Horz^[17] 2016). This review aims at discussing historical use of phage therapy and current research on the feasibility of phage-based infection control with a focus on multidrug-resistant infections.

PHAGE BIOLOGY BASICS

Phages are simple, yet incredibly diverse, non-living biological entities consisting of DNA or RNA enclosed within a protein capsid. As naturally-occurring bacterial parasites, phages are incapable of reproducing independently (*i.e.*, non-living) and are ultimately dependent on a bacterial host for survival. Phages typically bind to specific receptors on the bacterial cell surface, inject their genetic material into the host cell, and then either integrate this material into the bacterial genome (so-called “temperate” phages) and reproduce vertically from mother to daughter cell, or hijack the bacterial replication machinery to produce the next generation of phage progeny and lyse the cell (so-called “lytic” phages). Upon reaching a critical mass of phage progeny, which can be anywhere from a few to over 1000 viral particles depending on environmental factors, the lytic proteins become active and hydrolyze the peptidoglycan cell wall, releasing novel phage to reinitiate the lytic cycle^[18,19].

Most phages are infectious only to the bacteria that carry their complementary receptor, which, in turn, determines lytic phage host range^[20]. Host specificity varies among phages, some of which are strain-specific, whereas others have demonstrated the capability of infection across a range of bacterial strains and even genera^[21,22]. Bacteria have evolved numerous mechanisms to resist infection by lytic phages, and phages have an equally impressive diversity of mechanisms for breaking this resistance. For bacteria, this can include alteration or loss of receptors and integration of phage DNA into the clustered regularly interspaced palindromic repeats/CRISPR associated system (CRISPR/Cas) system^[23], while for phage this can include recognition of new or altered receptors and anti-CRISPR genes^[24]. The most common lytic phages associated with human pathogens and the gut microbiota are in the orders *Caudovirales*, commonly known as “tailed phages” which contain double-stranded DNA genomes, and *Microviridae*, which are tailless, single-stranded DNA viruses^[25,26].

In contrast to lytic phage, lysogenic phages integrate their genetic material into the bacterial chromosome in the form of an endogenous prophage (less commonly

phage DNA can remain separate as a plasmid but still be stably transmitted across bacterial generations). The bacterial lysogen then propagates the prophage with each cell division. Environmental stressors on the bacterial host are capable of inducing the lysogenic phage from the latent prophage form, triggering a transition to the lytic cycle and the release of phage progeny into the environment. When incorporating their genetic material into the bacterial genome, prophage-encoded genes become available for transcription by the host. Up to 18 prophages have been found in one bacterial genome, as in the food pathogen *Escherichia coli* (*E. coli*) O157:H7 strain Sakai^[27], with prophage-encoded genes comprising up to 20% of bacterial chromosomal content^[28]. These genes can be beneficial to the bacterial host and can encode for virulence factors (*e.g.*, diphtheria toxin, shiga toxin, and botulinum toxin), metabolic genes, and antibiotic resistance genes (*e.g.*, β -lactamases)^[29-32]. Phage biologists now recognize that phage lifecycles fall on a spectrum between these two extremes with pseudolysogenic, chronic, and cryptic lifecycles as examples of recent classifications^[19,33]. Conventional phage therapy relies on strictly lytic phages, which obligately kill their bacterial host. For treatment, lytic phages are compiled into preparations called “phage cocktails” which consist of multiple phages proven to have *in vitro* efficacy against the target pathogen.

HISTORY OF PHAGE THERAPY

Although the idea of using bacterial viruses therapeutically against bacterial infections has recently gained traction in response to the emergence of multidrug-resistant pathogens, the practice has been around for nearly a century. Since the initial observations of phage-induced bacterial lysis, the biological nature of phage, as well as their therapeutic value, has been controversial. Frederick Twort first described the characteristic zone of lysis associated with phage infection in 1915, but it was Felix d’Herelle who identified the source of this phenomenon, attributed the plaques to bacterial viruses, and coined the term “bacteriophage” (literally “bacteria-eater”). It was also d’Herelle who conceived of the idea to use phages therapeutically and is responsible for the first documented clinical use of phage in 1919 at the Hôpital des Enfants-Malades in Paris where phages were successfully used to treat 4 pediatric cases of bacterial dysentery^[1]. Despite several successful trials, d’Herelle’s early experiments were notorious for being poorly controlled and his research was vigorously disputed by the scientific community^[3]. Nevertheless, d’Herelle continued to pioneer phage therapy with the treatment of dysentery, cholera, and the bubonic plague in the early 20th century with a series of phage therapy centers and commercial phage production plants throughout Europe and India^[34]. One 1931 trial of phage therapy as a treatment for cholera in the Punjab region of India involved a cohort of 118 control

subjects and 73 experimental subjects who received phage treatment; d'Herelle observed a 90% reduction in mortality with 74 lethal outcomes in the control group and only 5 in the experimental group^[1].

Along with d'Herelle, several other entrepreneurs attempted to commercialize phage production in Brazil and the United States with phage preparations for *Staphylococcus*, *Streptococcus*, *E. coli*, and other bacterial pathogens^[34]. These preparations were shipped throughout the world to willing clinicians but treatment was met with mixed success; this lack of reliability, in large part, added to the preference for antibiotics in western medicine^[1].

Many mistakes were made during these early trials of phage therapy and most can be attributed to a poor understanding of the biological nature of phages. Rudimentary purification and storage protocols resulted in low titers of active phage, contamination from bacterial antigens, and the inappropriate choice of a phage that lacked specificity to the target pathogen. Furthermore, delivery of phage to the site of infection was confounded by the medical limitations of the day. For example, the role of the patient's innate immune response in removing active phage and diminishing the efficacy of phage therapy was only observed recently as a potentially confounding physiological mechanism^[35]. As a result, phage therapy was widely dismissed by most of western medicine after the introduction of pharmaceutical antibiotics in the 1940's. The exception to this is in the former Soviet Union and Eastern Europe where clinical phage therapy has been used extensively to treat antibiotic-resistant infections caused by a range of infectious bacteria such as *Staphylococcus*, *Pseudomonas*, *Klebsiella*, and *E. coli*^[36,37].

PHAGE AGAINST CLINICALLY SIGNIFICANT PATHOGENS

Recent investigations using animal models have explored phage treatment against a range of clinically significant pathogens. When challenged with gut-derived sepsis due to *P. aeruginosa*, oral administration of phage saved 66.7% of mice from mortality compared to 0% in the control group^[38]. In a hamster model of *Clostridium difficile* (*C. difficile*)-induced ileocectitis, a single dose of phage concurrent with *C. difficile* administration was sufficient prophylaxis against infection; phage treatments post-infection saved 11 of 12 mice whereas control animals receiving *C. difficile* and clindamycin died within 96 h^[39]. Phage combinations also significantly reduced *C. difficile* growth *in vitro* and limited proliferation *in vivo* using a hamster model^[40]. Intraperitoneal administration of a single phage strain was sufficient to rescue 100% of mice in bacteremia models using vancomycin-resistant *E. faecium*^[41], extended spectrum β -lactamase producing *E. coli*^[42], and imipenem-resistant *P. aeruginosa*^[43]. Phage cocktails have also been used

to treat antibiotic-resistant *P. aeruginosa* infections of the skin, lungs, and gastrointestinal tract in animal models^[38,44]. Additional animal studies show similarly promising results for multidrug-resistant *E. coli* O25:H4-ST131^[45], *Vibrio parahaemolyticus*^[46], *S. aureus*^[44,47], and *A. baumannii*^[38]. There is even an indication that phage are capable of restoring antibiotic sensitivity in antibiotic-resistant bacteria, as in the case of multidrug-resistant *P. aeruginosa*^[48].

Human trials for phage therapy have taken place for almost a century at several institutes in Eastern Europe, the most famous of which are the Eliava Institute of Bacteriophage and the Institute of Immunology and Experimental Therapy in Wroclaw, Poland. The Eliava Institute has extensively used phage in preclinical and clinical treatment of common bacterial pathogens such as *S. aureus*, *E. coli*, *Streptococcus* spp., *P. aeruginosa*, *Proteus* spp., *S. dysenteriae*, *Salmonella* spp., and *Enterococcus* spp.^[49]. Effective applications range from surgical to gastroenterological, both therapeutic and prophylactic. In a six patient case series of antibiotic-unresponsive diabetic foot ulcers, topical application of *S. aureus*-specific phage was sufficient for recovery in all individuals^[50]. In a 1938 clinical trial, 219 patients with bacterial dysentery (138 children and 81 adults) were treated solely with a phage cocktail consisting of a variety of phage targeting *Shigella flexneri*, *Shigella shiga*, *E. coli*, *Proteus* spp., *P. aeruginosa*, *Salmonella typhi*, *Salmonella paratyphi* A and B, *Staphylococcus* spp., *Streptococcus* spp. and *Enterococcus* spp.; cocktails were administered both orally and rectally. Within 24 h, 28% of patients with blood in their stools were relieved of this symptom, with a further 27% showing improvement within 2-3 d. Overall, 74% of the 219 patients showed improvement or were completely relieved of symptoms^[51]. Additionally, during a 1974 typhoid epidemic, a cohort of 18577 children was enrolled in a prophylactic intervention trial using typhoid phages. Phage administration resulted in a 5-fold decrease in typhoid incidence compared to placebo^[49]. The potential for phage therapy has yet to be fully realized since phages tend to be more effective against the target pathogen when used in combination with antibiotics^[52], a treatment option that has not yet been investigated in humans.

Currently there are no phage therapy products approved for human use in the EU or United States. However, in the food industry, there are several commercial phage preparations used for biocontrol of bacterial pathogens that are approved by the FDA under the classification of "generally considered as safe." These preparations are used against *Salmonella* spp., *Listeria monocytogenes*, MRSA, *E. coli* O157:H7, *Mycobacterium tuberculosis*, *Campylobacter* spp., and *Pseudomonas syringae*, among others^[53-56]. Phages also have potential value for pathogen detection, an example of which is using bioluminescent reporter phage to detect *Bacillus anthracis*^[56]. In 2011 there was an estimated 48 million cases of food poisoning in the United States alone^[55].

Table 1 Published findings on phage therapy in humans and in animal models

Causative agent	Model	Condition	Oral	Result summary ¹	Ref.
<i>Shigella dysenteriae</i>	Human	Dysentery	Oral	All four treated individuals recovered after 24 h	[1]
<i>Vibrio cholerae</i>	Human	Cholera	Oral	68 of 73 survived in treatment group and only 44 of 118 in control group	[1]
<i>Pseudomonas aeruginosa</i>	Murine	Sepsis	Oral	66.7% reduced mortality	[38]
<i>Clostridium difficile</i>	Hamster	Ileocectitis	Oral	Co-administration with <i>C. difficile</i> prevented infection	[39]
	Hamster	Ileocectitis	Oral dose every 8 h for 72 h	92% reduced mortality	[39]
Vancomycin-resistant <i>Enterococcus faecium</i>	Murine	Bacteremia	i.p.	100% reduced mortality	[41]
β -lactamase producing <i>Escherichia coli</i>	Murine	Bacteremia	i.p.	100% reduced mortality	[42]
Imipenem-resistant <i>P. aeruginosa</i>	Murine	Bacteremia	i.p.	100% reduced mortality	[43]
<i>Acinetobacter baumannii</i> , <i>P. aeruginosa</i> and <i>Staphylococcus aureus</i>	Murine	Sepsis	i.p.	Animals protected against fatal dose of <i>A. baumannii</i> and <i>P. aeruginosa</i> but not <i>S. aureus</i>	[44]
<i>Escherichia coli</i>	Murine	Meningitis and Sepsis	i.p. or s.c.	100% and 50% reduced mortality for meningitis and sepsis, respectively	[45]
MDR <i>Vibrio parahaemolyticus</i>	Murine	Sepsis	i.p. and oral	92% and 84% reduced mortality for i.p. and oral routes, respectively	[46]
<i>S. aureus</i>	Rabbit	Wound infection	s.c.	Co-administration with <i>S. aureus</i> prevented infection	[47]
MDR <i>S. aureus</i>	Human	Diabetic foot ulcer	Topical	All 6 treated patients recovered	[50]
Unclassified bacterial dysentery	Human	Dysentery	Oral	Phage cocktail improved symptoms of 74% of 219 patients	[51]
<i>Salmonella typhi</i>	Human	Typhoid	Oral	In cohort of 18577 children, phage treatment associated with 5-fold decrease in typhoid incidence compared to placebo	[49]
Antibiotic-resistant <i>P. aeruginosa</i>	Human	Chronic Otitis	Oral	Phage treatment safe and symptoms improved in double-blind, placebo-controlled Phase I/II trial	[61]

¹Reduced mortality is for phage-treated groups and are relative to 100% mortality in control animals, unless otherwise specified. MDR: Multi-drug-resistant; i.p.: Intraperitoneal injection; s.c.: Subcutaneous injection.

Evidence suggests that phage biocontrol can be an effective method for improving food safety at numerous stages in meat production and processing, and also has potential to reduce bacterial contamination in fruits, vegetables, and dairy products^[55]. These investigations into phage biocontrol in food production, as well as recent placebo-controlled human trials that demonstrated the safety of oral phage administration^[57-60], are gradually beginning to fill the knowledge gap in phage therapy safety. The evidence on phage safety will continue to strengthen with further randomized, double-blind, and placebo-controlled phase I / II clinical trials of phage therapy, such as the one that established both safety and efficacy in treating chronic otitis caused by antibiotic-resistant *P. aeruginosa*^[61].

Innovations in the programmable gene editing tool CRISPR/Cas have created novel opportunities for phage therapy. One example of which is the use of bioengineered phage to deliver a CRISPR/Cas programmed to disrupt antibiotic resistance genes and destroy antibiotic resistance plasmids^[62]. These phages may be applied to hospital surfaces to reduce frequency and spread of antibiotic resistance genes. The field of bioengineered phages is still in its infancy but will undoubtedly yield many invaluable technologies such as this (Table 1).

DEVELOPMENT AND APPLICATION OF PHAGE-DERIVED LYTIC PROTEINS

Among the most promising of advances in phage therapy is the isolation of phage-encoded lytic enzymes, which are functionally similar to the eukaryotic enzyme lysozyme. Genes for these enzymes are expressed by the bacterial host during the lytic cycle and assist the phage by hydrolyzing the cell wall to release viral progeny. The discovery and analysis of these proteins opens the possibility for the development of novel phage-based pharmaceuticals.

Two major protein classes are employed by the majority of phage species during the lysis of the bacterial host. One of which is the transmembrane protein holin and the other is a peptidoglycan cell wall hydrolase called endolysin (lysin). These two proteins work together in triggering the lysis of the bacterial cell. The holin protein acts as a molecular "clock" in the lytic cycle. During the process of viral assembly within the cytoplasm, holin molecules accrue in the cell membrane. At the end of the lytic cycle the holin proteins trigger an opening on the cytoplasmic side of the cell membrane, allowing the lysin proteins to access and hydrolyze the cell wall^[63]. Although both of these enzymes are present

across the majority of phage species, there is huge structural and biochemical variability and therefore little sequence conservation among species. Each phage can encode for several unique lysin and holin enzymes, some of which are highly specific but others can exhibit broad-spectrum activity between strains and even between species as in the case of recently discovered lysin ABgp46. ABgp46 has the ability to lyse several gram-negative and multidrug-resistant pathogens, including *A. baumannii*, *P. aeruginosa*, and *Salmonella typhimurium*^[64].

Phage lysins alone are capable of bacterial cell lysis, whereas holins are not; therefore lysins have received a lot of attention as potential antimicrobial agents. These proteins are fast acting, potent, and inactive against eukaryotic cells. Lysins have successfully saved mice from bacteremia caused by multidrug-resistant *A. baumannii*^[65], *Streptococcus pneumoniae*^[66], and MRSA^[67], among others^[63]. A combination of phage lysins and antibiotics has been shown to be much more effective than antibiotics alone in eliminating *C. difficile* colonization in both an *in vitro* and an *ex vivo* colon model in the presence of intestinal contents^[68]. Not all lysins show equal therapeutic potential, however, as demonstrated by Gilmer *et al.*^[69] who identified a uniquely potent lysin, PlySs2, which was highly effective against a range of pathogenic *Streptococcus* and *Staphylococcus* species, including MRSA, and was fully functional after 10 freeze-thaws. A single dose administered intraperitoneally to mice in a mixed *S. pyogenes* and MRSA bacteremia model provided a significantly higher survival rate than treatment with 3 previously characterized lysins^[69]. A recent study exploring the isolation and application of phage proteins has revealed that lysins are even capable of crossing epithelial cell membranes to eliminate difficult to treat intracellular infections of *S. pyogenes*^[70]. In addition, phage lysins can disrupt vegetative cells such as in the case of *B. anthracis* lysin PlyG which is capable of attacking endospores of bacillus, a distinct advantage over antibiotics^[71]. Lysins can also be mass produced through common recombinant techniques. The gene for bacteriophage-derived cysteine, histidine-dependent amido hydrolase/peptidase (CHAPK) has been cloned and inserted into *E. coli* to be overexpressed for purification. Not only is the CHAPK lysin highly effective against MRSA, but it can disperse *S. aureus* biofilms^[72].

Efforts to optimize lysins through bioengineering have yielded some promising results. Yang *et al.*^[73] produced a novel chimeric lysin, by combining the active site of a lysin with a cell wall binding domain, that was capable of saving mice challenged with MRSA bacteremia. Research on chimeric lysin enzymes is still in the early stages, but some of these modified lysins have also been shown to prevent death from *S. pneumoniae* bacteremia^[74] and prevent development of methicillin-sensitive *S. aureus* endophthalmitis in a mouse model^[75]. Since lysins act by enzymatically cleaving the bacterial cell wall, they are inherently less

effective against gram-negative bacteria which have an impermeable lipopolysaccharide outer membrane. In an attempt to broaden lysin activity to target gram-negative pathogens, several researchers have begun to bioengineer artificial lysin molecules, termed Artilyns, that are capable of penetrating the outer membrane. Some of these lysins are created by combining the active site of the lysin enzyme with lipopolysaccharide-destabilizing peptides which allows the molecule to penetrate the outer membrane. So far Artilyns have been shown to decolonize *P. aeruginosa* in a nematode gut model and protect human keratinocytes when challenged with *A. baumannii*^[76].

Adding to the appeal of lysins as antibacterial agents, it is widely considered unlikely that bacteria will evolve resistance to lysins due to the fact that they target sites on the peptidoglycan cell wall critical for bacterial viability^[63]. Engineered recombinant phage lytic proteins would be far easier to mass produce and administer than preparations of actual phage, which can be limited by a short shelf life, removal by the reticuloendothelial system of the host, and the potential for generating neutralizing antibodies^[35]. Future potential for phage lysin application includes combination therapy of lysins in conjunction with antibiotics, which has been shown to be more effective than antibiotics or lysins alone against pathogens such as MRSA and *C. difficile* in a murine model^[77-79] (Table 2).

PHAGE THERAPY VS ANTIBIOTIC THERAPY

Both antibiotics and phages function as antibacterials that disrupt bacterial colonies through lysis or inhibition, yet several key differences make each antibacterial more or less appropriate depending on the situation.

Safety

Adverse reactions to antibiotics are well documented and include instances of anaphylaxis, nephrotoxicity, cardiotoxicity, hepatotoxicity, and neurotoxicity, as well as a number of gastrointestinal and hematological complications^[80]. The majority of adverse reactions are allergic reactions and in these rare instances, the anaphylaxis is associated with specific classes of antibiotics or is the product of high tissue concentrations^[81-83]. In contrast to the comprehensive literature on antibiotic safety, phage therapy has only recently gained attention by western medicine and, as a result, much of the available information on phage safety is new. Although oral phage administration is generally considered to be safe^[57-60], a major consideration for phage therapy is the translocation of phage across the intestinal epithelium where they subsequently circulate within the blood^[84]. Some data show that phage translocation may benefit the host by downregulating the immune response to indigenous gut microbe antigens through the inhibition of interleukin-2, tumor necrosis

Table 2 Recently published findings on phage lytic enzymes

	Lytic enzyme	Model	Target pathogens	Result summary	Ref.
Phage-derived lysins	ABgp46	<i>In vitro</i>	MDR <i>Acinetobacter baumannii</i> , <i>Pseudomonas aeruginosa</i> , and <i>Salmonella typhimurium</i>	Cross-inoculation significantly reduced bacterial density	[64]
	PlyF307	Murine	MDR <i>A. baumannii</i>	<i>i.p.</i> treatment rescued mice from lethal bacteremia	[65]
	Cpl-1	Murine	<i>Streptococcus pneumoniae</i>	<i>i.p.</i> treatment rescued mice from lethal pneumonia	[66]
	Cocktail of 6 distinct lysins	<i>In vitro</i> and murine <i>in vivo</i>	MRSA	Effective against biofilms <i>in vitro</i> and protected mice from lethal sepsis	[67]
	PlyCD	<i>In vitro</i> and <i>ex vivo</i>	<i>Clostridium difficile</i>	Reduced <i>C. difficile</i> colonization	[68]
	PlySs2	Murine	<i>Streptococcus pyogenes</i> and MRSA	<i>i.p.</i> treatment reduced mortality from lethal bacteremia	[69]
	PlyG	<i>In vitro</i>	<i>Bacillus anthracis</i>	Eliminated <i>B. anthracis</i> spores and vegetative cells	[71]
Bioengineered chimeric lysins	CHAPK	<i>In vitro</i>	MRSA	Eliminated MRSA and dispersed biofilms	[72]
	ClyH	Murine	MRSA	Treatment rescued mice from bacteremia	[73]
	Cpl-711	Murine	<i>S. pneumoniae</i>	Treatment rescued mice from bacteremia	[74]
	Ply187	Murine	<i>Staphylococcus aureus</i>	Prevented bacterial endophthalmitis	[75]
	Artilyns	Nematode gut	<i>P. aeruginosa</i>	Decolonized <i>P. aeruginosa</i> from gut	[76]
		Human keratinocytes	<i>A. baumannii</i>	Protected cells from bacterial challenge	[76]
Lysin and antibiotic combination therapy	CF-301	Murine	MRSA	Lysin treatment was most effective when combined with vancomycin or daptomycin	[77]
	MR-10	Murine	Burn wound infection	Lysin treatment was most effective when combined with minocycline	[78]

MDR: Multi-drug-resistant; *i.p.*: Intraperitoneal injection; MRSA: Methicillin-resistant *S. aureus*.

factor, and interferon gamma production^[84]. Other studies discovered a host innate immune response aimed at removing phage after administration in mice^[35,85]. While potentially beneficial in a healthy individual, the immunological response to phage may be indicative of a potential adverse immunogenicity of phage in immunocompromised patients, which could hypothetically worsen a patient's condition. On the contrary, other researchers argue it is unlikely phage therapy will elicit such an adverse response in immunocompromised patients^[86].

Additional complications include the possibility that phage cocktails induce a state of intestinal barrier dysfunction, otherwise known as "leaky gut". Tetz and Tetz used a mouse model to demonstrate that oral administration of a commercial Russian phage cocktail was capable of increasing intestinal permeability and elevating serum levels of inflammatory circulating immune complexes in the blood, which are associated with a number of pathological conditions^[87]. However, another study observed no significant increase in cytokine levels in response to phage treatment^[88]. The potential for phage therapy to disrupt normal intestinal barrier function would have serious implications for several disorders recently linked to intestinal barrier dysfunction such as Crohn's disease, inflammatory bowel disease, and type 1 diabetes^[87]. Pincus *et al.*^[89] found that inflammatory response to phage was dependent on site of infection. Clearly, many considerations for the safety of phage therapy still need to be addressed. It is likely that the physiological response to phages also differs between individuals and is dependent on the specific phage strains used. To determine the safety of

phage treatments in regards to human health, future investigations will need to focus on human clinical trials as much of the current research on the immunological response to phage is limited to animal models.

Specificity

Relative to antibiotics, phages tend to be specific towards both species and strain. In certain situations this can be a major advantage considering the well-documented, collateral effects of broad-spectrum antibiotics on commensal gut microbes, which are notorious for secondary outcomes such as antibiotic-associated diarrhea and *C. difficile* infection^[90]. Other consequences of antibiotic perturbations in the gut microbial community include risk of asthma, obesity, and diabetes^[91-93]. The current understanding of collateral damage due to phage therapy is limited, but compared to antibiotics, phage therapy has been reported to result in less perturbation of the gut microbiome while still effectively reducing gut carriage of pathogens such as *Shigella sonnei* and uropathogenic *E. coli*^[94,95].

Strain and species specificity of antibacterial action has many advantages, however, increased specificity also comes with several limitations. By targeting a single pathogen, phage therapy could be less effective against certain infections, such as infected burn wounds, which are often colonized by more than one strain of bacteria^[96]. This can be accounted for by creating phage cocktails infective against a range of known pathogens, but the success of this approach depends on knowledge of which pathogens are being treated. With regard to logistical considerations, this

specificity significantly impacts treatment development and testing, and also limits the possibility of large-scale production and distribution, a distinct advantage of broad-spectrum antibiotics. Bourdin *et al.*^[15] cross-inoculated phages from 2 distinct geographic regions (Mexico and Bangladesh) against diarrhea-associated *E. coli* from the same regions and found that phage showed high strain specificity to the *E. coli* of their indigenous region. In a randomized clinical trial, Sarker *et al.*^[60] administered a commonly used Russian *E. coli* phage cocktail to a cohort of 120 Bangladeshi children with microbiologically-proven enterotoxigenic *E. coli* diarrhea. No improvement of clinical outcome was observed in patients receiving the phage cocktail compared to placebo^[60]. These findings are in line with the *in vitro* work that suggests phage cocktails are better adapted to local bacterial populations^[15], and bacterial host range can be restricted both spatially and temporally^[97]. In contrast, in an *in vitro* cross-inoculation of a phage cocktail against shiga toxin-producing *E. coli* O157:H7, lysis occurred in isolates of both human and bovine origin, suggesting the possibility of regional phage cocktails for both clinical and agricultural settings^[98]. Latz *et al.*^[99] found that phages targeting antibiotic-resistant bacteria are more likely to be found within the environment of the infected patient, which, in this case, was the hospital effluent where the antibiotic-resistant bacteria were isolated.

Regional specificity may be helpful in finding phages with the greatest infectivity towards the target pathogen, this would especially benefit regions with limited access to antibiotics. Together, the mounting evidence for the local adaptivity of phage suggests that regulatory pipelines must also be rapidly adaptable (*i.e.*, allowing for the replacement or addition of phages into cocktails without requiring further clinical trials) for phage therapy to work on a global scale.

Biofilm penetration

Antibiotic therapy is highly effective with planktonic bacteria, such as *V. cholerae* and *Yersinia pestis*, yet is limited in treating biofilm-based bacterial infection^[100]. Phages, however, are equipped with enzymes (*e.g.*, EPS depolymerase) on the exterior of the capsid that degrade the extracellular polymeric substances (EPS) and disperse bacterial biofilms, allowing the phage to access bacteria embedded within the EPS matrix^[83]. The phage progeny released upon completion of the lytic cycle propagate the dispersal of the biofilm through the removal of biofilm-embedded bacteria in subsequent layers^[83,101]. In order to penetrate dense biofilms, high doses of antibiotics are typically required to observe any inhibition of bacterial growth, yet complete eradication is rare and regrowth of colonies begins after the end of antibiotic treatments^[102,103]. Although low concentrations of many antibiotics are generally considered non-toxic, high concentrations of antibiotics can result in tissue toxicity^[83]. Gabisoniya *et al.*^[104] at the Eliava Institute of Bacteriophages in Tbilisi, Georgia found

that the application of phages on *in vitro* colonies of the pathogen *P. aeruginosa* not only prevented additional biofilm formation by the pathogen but also degraded existing biofilm. Phage treatments have eliminated biofilms formed by *L. monocytogenes*, *P. aeruginosa*, and *Staphylococcus epidermidis* on the surface of medical devices^[22]. These findings are highly relevant to the problem of persistent infections caused by implanted medical devices such as catheters, lenses, and prostheses where biofilm formation is common.

Phage cocktails

Due to the massive diversity of environmental phages, designing a phage cocktail is substantially more complicated than designing a regimen for combination antibiotic therapy. Composition of the phage cocktail is critical for the success of phage therapy. Factors in the construction of a phage cocktail are beyond the scope of this review and have been thoroughly discussed elsewhere^[105], but one of the major logistical challenges is whether to approach phage therapy with a standardized or a customized cocktail. Customizing phage cocktails to each infection is time consuming and costly but on the other end of the spectrum, a "one-size-fits-all" approach may not provide the strain specificity required for favorable clinical outcomes^[105]. Other considerations are the collateral effects of phages on the indigenous microbiota, a topic that has not yet been fully explored^[88,94,95]. In cocktail design, one must also take into account phage lifecycle. Lysogenic phages appear to be very common in the indigenous gut microbiota, with prophages comprising the majority of the gut virome^[25]. Some therapeutically promising lysogenic phages effectively silence virulence genes in pathogenic bacteria or provide genes for short chain fatty acid metabolism, whereas other lysogenic phages supplement genes for virulence and antibiotic resistance^[29,30,106].

Antibiotic resistance genes have been collected from the phage fraction of DNA in wastewater and have been reported to persist longer in phage when compared to bacteria^[107]. Antibiotic resistance genes are also present in the phage fraction of human fecal samples and antibiotic treatment in mice enriches the abundance of phage-encoded antibiotic resistance genes, indicating a possible role for phages as a reservoir for antibiotic resistance genes^[30-32]. The hypothetical potential for lysogenic phages to complicate existing infections through the horizontal transfer of antibiotic resistance genes to infectious bacteria largely excludes them from consideration for most phage cocktails. Yet, Regeimbal *et al.*^[106] demonstrated the possibility for an innovative application of lysogenic phages by designing an "intelligent" 5 phage cocktail that eliminated *A. baumannii* skin wound infection in a mouse model. This intelligent phage cocktail was composed of 4 phages that were incapable of lysing the *A. baumannii* host and 1 phage that only inhibited growth *in vitro*. The growth-inhibiting phage targeted capsulated *A. baumannii*, selecting for

the loss of the capsule. The removal of the capsule, a known virulence factor, decreased the virulence of the bacterium and made it susceptible to lysis from the 4 additional phages^[106]. This “intelligent” cocktail represents the beginning of novel treatment options for eliminating bacterial infections that are resistant to conventional treatment. Lysogenic phages have many intriguing properties that may be useful for this type of *in situ* manipulation of individual bacterium, and potentially the human gut microbiome metagenome^[108], but first much more needs to be known about the role of lysogenic phages in the human gut phageome for this to be done safely and effectively.

CONCLUSION

The available literature on the use of phages and phage-derived proteins for combating bacterial infections, specifically those of multidrug-resistant bacteria, increasingly shows promise for the prospect of phage therapy as either an alternative or a supplement to antibiotics. However, recent findings on the immunomodulatory effects of phages make it abundantly clear that we need a better understanding of the interaction between phage, microbiome, and human host before implementing phage therapy on a large scale. Phage lysins may thus be a much more practical therapeutic tool for their decreased immunological potential, among other reasons such as ease of production, purification, and storage. In spite of the promise offered by phage and phage-derived lytic proteins, it is more than likely that no panacea for antibiotic-resistant infections will arise. The increased efficacy of antibacterial agents when used in conjunction implies that therapy using some combination of phage, phage-derived lytic proteins, bioengineered phage, and/or antibiotics will be necessary for addressing the growing problem of antibiotic-resistant infections.

REFERENCES

- 1 **Chanishvili N.** Phage therapy--history from Twort and d'Herelle through Soviet experience to current approaches. *Adv Virus Res* 2012; **83**: 3-40 [PMID: 22748807 DOI: 10.1016/B978-0-12-394438-2.00001-3]
- 2 **Suttle CA.** Marine viruses--major players in the global ecosystem. *Nat Rev Microbiol* 2007; **5**: 801-812 [PMID: 17853907 DOI: 10.1038/nrmicro1750]
- 3 **Wittebole X, De Roock S, Opal SM.** A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. *Virulence* 2014; **5**: 226-235 [PMID: 23973944 DOI: 10.4161/viru.25991]
- 4 **Ackermann HW.** The first phage electron micrographs. *Bacteriophage* 2011; **1**: 225-227 [PMID: 23050215 DOI: 10.4161/bact.1.4.17280]
- 5 **Yoshikawa TT.** Antimicrobial resistance and aging: beginning of the end of the antibiotic era? *J Am Geriatr Soc* 2002; **50**: S226-S229 [PMID: 12121517]
- 6 **Hicks LA, Bartoces MG, Roberts RM, Suda KJ, Hunkler RJ, Taylor TH, Schrag SJ.** US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. *Clin Infect Dis* 2015; **60**: 1308-1316 [PMID: 25747410 DOI: 10.1093/cid/civ076]
- 7 **Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O.** Antibiotic resistance--the need for global solutions. *Lancet Infect Dis* 2013; **13**: 1057-1098 [PMID: 24252483 DOI: 10.1016/S1473-3099(13)70318-9]
- 8 **Zhang XX, Zhang T, Fang HH.** Antibiotic resistance genes in water environment. *Appl Microbiol Biotechnol* 2009; **82**: 397-414 [PMID: 19130050 DOI: 10.1007/s00253-008-1829-z]
- 9 **Centers for Disease Control.** Antibiotic Resistance: The Global Threat. 2015; Accessed Mar 29, 2017. Available from: URL: https://www.cdc.gov/drugresistance/pdf/antibiotic_resistant_fs.pdf
- 10 **World Health Organization.** Antibiotic resistance - a threat to global health security. 2013. Accessed Mar 29, 2017. Available from: URL: http://www.who.int/drugresistance/activities/wha66_side_event/en/
- 11 **Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J.** Bad bugs, no drugs: no ESCAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis* 2009; **48**: 1-12 [PMID: 19035777 DOI: 10.1086/595011]
- 12 **Luepke KH, Suda KJ, Boucher H, Russo RL, Bonney MW, Hunt TD, Mohr JF.** Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications. *Pharmacotherapy* 2017; **37**: 71-84 [PMID: 27859453 DOI: 10.1002/phar.1868]
- 13 **Centers for Disease Control and Prevention.** Vital signs: carbapenem-resistant Enterobacteriaceae. *MMWR Morb Mortal Wkly Rep* 2013; **62**: 165-170 [PMID: 23466435]
- 14 **United Nations.** PRESS RELEASE: High-Level Meeting on Antimicrobial Resistance. 2016; Accessed Mar 29, 2017. Available from: URL: <http://www.un.org/pga/71/2016/09/21/press-release-hl-meeting-on-antimicrobial-resistance/>
- 15 **Bourdin G, Navarro A, Sarker SA, Pittet AC, Qadri F, Sultana S, Cravioto A, Talukder KA, Reuteler G, Brüssow H.** Coverage of diarrhoea-associated *Escherichia coli* isolates from different origins with two types of phage cocktails. *Microb Biotechnol* 2014; **7**: 165-176 [PMID: 24528873 DOI: 10.1111/1751-7915.12113]
- 16 **Donlan RM.** Preventing biofilms of clinically relevant organisms using bacteriophage. *Trends Microbiol* 2009; **17**: 66-72 [PMID: 19162482 DOI: 10.1016/j.tim.2008.11.002]
- 17 **Wahida A, Ritter K, Horz HP.** The Janus-Face of Bacteriophages across Human Body Habitats. *PLoS Pathog* 2016; **12**: e1005634 [PMID: 27337144 DOI: 10.1371/journal.ppat.1005634]
- 18 **Delbrück M.** The growth of bacteriophage and lysis of the host. *J Gen Physiol* 1940; **23**: 643-660 [PMID: 19873180]
- 19 **Weinbauer MG.** Ecology of prokaryotic viruses. *FEMS Microbiol Rev* 2004; **28**: 127-181 [PMID: 15109783 DOI: 10.1016/j.femsre.2003.08.001]
- 20 **Rakhuba DV, Kolomiets EI, Dey ES, Novik GI.** Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell. *Pol J Microbiol* 2010; **59**: 145-155 [PMID: 21033576]
- 21 **Koskella B, Meaden S.** Understanding bacteriophage specificity in natural microbial communities. *Viruses* 2013; **5**: 806-823 [PMID: 23478639 DOI: 10.3390/v5030806]
- 22 **Motlagh AM, Bhattacharjee AS, Goel R.** Biofilm control with natural and genetically-modified phages. *World J Microbiol Biotechnol* 2016; **32**: 67 [PMID: 26931607 DOI: 10.1007/s11274-016-2009-4]
- 23 **Labrie SJ, Samson JE, Moineau S.** Bacteriophage resistance mechanisms. *Nat Rev Microbiol* 2010; **8**: 317-327 [PMID: 20348932 DOI: 10.1038/nrmicro2315]
- 24 **Koskella B, Brockhurst MA.** Bacteria-phage coevolution as a driver of ecological and evolutionary processes in microbial communities. *FEMS Microbiol Rev* 2014; **38**: 916-931 [PMID: 24617569 DOI: 10.1111/1574-6976.12072]
- 25 **Minot S, Sinha R, Chen J, Li H, Keilbaugh SA, Wu GD, Lewis JD, Bushman FD.** The human gut virome: inter-individual variation and dynamic response to diet. *Genome Res* 2011; **21**: 1616-1625 [PMID: 21880779 DOI: 10.1101/gr.122705.111]
- 26 **Reyes A, Haynes M, Hanson N, Angly FE, Heath AC, Rohwer F, Gordon JL.** Viruses in the faecal microbiota of monozygotic twins and

- their mothers. *Nature* 2010; **466**: 334-338 [PMID: 20631792 DOI: 10.1038/nature09199]
- 27 **Ohnishi M**, Kurokawa K, Hayashi T. Diversification of *Escherichia coli* genomes: are bacteriophages the major contributors? *Trends Microbiol* 2001; **9**: 481-485 [PMID: 11597449]
- 28 **Hatfull GF**, Hendrix RW. Bacteriophages and their genomes. *Curr Opin Virol* 2011; **1**: 298-303 [PMID: 22034588 DOI: 10.1016/j.coviro.2011.06.009]
- 29 **Penadés JR**, Chen J, Quiles-Puchalt N, Carpena N, Novick RP. Bacteriophage-mediated spread of bacterial virulence genes. *Curr Opin Microbiol* 2015; **23**: 171-178 [PMID: 25528295 DOI: 10.1016/j.mib.2014.11.019]
- 30 **Modi SR**, Lee HH, Spina CS, Collins JJ. Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome. *Nature* 2013; **499**: 219-222 [PMID: 23748443 DOI: 10.1038/nature12212]
- 31 **Quirós P**, Colomer-Lluch M, Martínez-Castillo A, Miró E, Argente M, Jofre J, Navarro F, Muniesa M. Antibiotic resistance genes in the bacteriophage DNA fraction of human fecal samples. *Antimicrob Agents Chemother* 2014; **58**: 606-609 [PMID: 24165177 DOI: 10.1128/AAC.01684-13]
- 32 **Colomer-Lluch M**, Jofre J, Muniesa M. Antibiotic resistance genes in the bacteriophage DNA fraction of environmental samples. *PLoS One* 2011; **6**: e17549 [PMID: 21390233 DOI: 10.1371/journal.pone.0017549]
- 33 **Wang X**, Wood TK. Cryptic prophages as targets for drug development. *Drug Resist Updat* 2016; **27**: 30-38 [PMID: 27449596 DOI: 10.1016/j.drup.2016.06.001]
- 34 **Sulakvelidze A**, Alavidze Z, Morris JG. Bacteriophage therapy. *Antimicrob Agents Chemother* 2001; **45**: 649-659 [PMID: 11181338 DOI: 10.1128/AAC.45.3.649-659.2001]
- 35 **Hodyra-Stefaniak K**, Miernikiewicz P, Drapała J, Drab M, Jończyk-Matysiak E, Lecion D, Kaźmierczak Z, Beta W, Majewska J, Harhala M, Bubak B, Kłopot A, Górski A, Dąbrowska K. Mammalian Host-Versus-Phage immune response determines phage fate in vivo. *Sci Rep* 2015; **5**: 14802 [PMID: 26440922 DOI: 10.1038/srep14802]
- 36 **Carlton RM**. Phage therapy: past history and future prospects. *Arch Immunol Ther Exp (Warsz)* 1999; **47**: 267-274 [PMID: 10604231]
- 37 **Weber-Dabrowska B**, Mulczyk M, Górski A. Bacteriophage therapy of bacterial infections: an update of our institute's experience. *Arch Immunol Ther Exp (Warsz)* 2000; **48**: 547-551 [PMID: 11197610]
- 38 **Watanabe R**, Matsumoto T, Sano G, Ishii Y, Tateda K, Sumiyama Y, Uchiyama J, Sakurai S, Matsuzaki S, Imai S, Yamaguchi K. Efficacy of bacteriophage therapy against gut-derived sepsis caused by *Pseudomonas aeruginosa* in mice. *Antimicrob Agents Chemother* 2007; **51**: 446-452 [PMID: 17116686 DOI: 10.1128/AAC.00635-06]
- 39 **Ramesh V**, Fralick JA, Rolfe RD. Prevention of *Clostridium difficile*-induced ileocectitis with bacteriophage. *Anaerobe* 1999; **5**: 69-78 [DOI: 10.1006/anae.1999.0192]
- 40 **Nale JY**, Spencer J, Hargreaves KR, Buckley AM, Trzepeński P, Douce GR, Clokie MR. Bacteriophage Combinations Significantly Reduce *Clostridium difficile* Growth In Vitro and Proliferation In Vivo. *Antimicrob Agents Chemother* 2016; **60**: 968-981 [PMID: 26643348 DOI: 10.1128/AAC.01774-15]
- 41 **Biswas B**, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merrill CR. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant *Enterococcus faecium*. *Infect Immun* 2002; **70**: 204-210 [PMID: 11748184]
- 42 **Wang J**, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Tao D, Ding L, Reed E, Gong J, Li QQ, Hu J. Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing *Escherichia coli* bacteremia. *Int J Mol Med* 2006; **17**: 347-355 [PMID: 16391836 DOI: 10.3892/ijmm.17.2.347]
- 43 **Wang J**, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Reed E, Ding L, Gong J, Li QQ, Hu J. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant *Pseudomonas aeruginosa*. *Int J Mol Med* 2006; **17**: 309-317 [PMID: 16391831]
- 44 **Soothill JS**. Treatment of experimental infections of mice with bacteriophages. *J Med Microbiol* 1992; **37**: 258-261 [PMID: 1404324 DOI: 10.1099/00222615-37-4-258]
- 45 **Pouillot F**, Chomton M, Blois H, Courroux C, Noelig J, Bidet P, Bingen E, Bonacorsi S. Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b: H4-ST131 *Escherichia coli* strain producing CTX-M-15. *Antimicrob Agents Chemother* 2012; **56**: 3568-3575 [PMID: 22491690 DOI: 10.1128/AAC.06330-11]
- 46 **Jun JW**, Shin TH, Kim JH, Shin SP, Han JE, Heo GJ, De Zoysa M, Shin GW, Chai JY, Park SC. Bacteriophage therapy of a *Vibrio parahaemolyticus* infection caused by a multiple-antibiotic-resistant O3: K6 pandemic clinical strain. *J Infect Dis* 2014; **210**: 72-78 [PMID: 24558119 DOI: 10.1093/infdis/jiu059]
- 47 **Wills QF**, Kerrigan C, Soothill JS. Experimental bacteriophage protection against *Staphylococcus aureus* abscesses in a rabbit model. *Antimicrob Agents Chemother* 2005; **49**: 1220-1221 [PMID: 15728933 DOI: 10.1128/AAC.49.3.1220-1221.2005]
- 48 **Chan BK**, Siström M, Wertz JE, Kortright KE, Narayan D, Turner PE. Phage selection restores antibiotic sensitivity in MDR *Pseudomonas aeruginosa*. *Sci Rep* 2016; **6**: 26717 [PMID: 27225966 DOI: 10.1038/srep26717]
- 49 **Kutateladze M**, Adamia R. Phage therapy experience at the Eliava Institute. *Med Mal Infect* 2008; **38**: 426-430 [PMID: 18687542 DOI: 10.1016/j.medmal.2008.06.023]
- 50 **Fish R**, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S. Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. *J Wound Care* 2016; **25** Suppl 7: S27-S33 [PMID: 27410468 DOI: 10.12968/jowc.2016.25.7.S27]
- 51 **Chanishvili N**, Sharp R. Bacteriophage therapy: experience from the Eliava Institute, Georgia. *Microbiol Australia* 2008; **29**: 96-101 [DOI: 10.1071/MA08096]
- 52 **Kutateladze M**, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. *Trends Biotechnol* 2010; **28**: 591-595 [PMID: 20810181 DOI: 10.1016/j.tibtech.2010.08.001]
- 53 **Monk AB**, Rees CD, Barrow P, Hagens S, Harper DR. Bacteriophage applications: where are we now? *Lett Appl Microbiol* 2010; **51**: 363-369 [PMID: 20796209 DOI: 10.1111/j.1472-765X.2010.02916.x]
- 54 **Nannapaneni R**, Soni KA. Use of Bacteriophages to Remove Biofilms of *Listeria monocytogenes* and other Foodborne Bacterial Pathogens in the Food Environment. *Biofilms in the Food Environment*, Second Edition. USA: John Wiley & Sons, Ltd., 2015: 131-144 [DOI: 10.1002/9781118864036.ch5]
- 55 **Endersen L**, O'Mahony J, Hill C, Ross RP, McAuliffe O, Coffey A. Phage therapy in the food industry. *Annu Rev Food Sci Technol* 2014; **5**: 327-349 [PMID: 24422588 DOI: 10.1146/annurev-food-030713-092415]
- 56 **Schofield DA**, Sharp NJ, Vandamm J, Molineux IJ, Spreng KA, Rajanna C, Westwater C, Stewart GC. *Bacillus anthracis* diagnostic detection and rapid antibiotic susceptibility determination using 'bioluminescent' reporter phage. *J Microbiol Methods* 2013; **95**: 156-161 [PMID: 23994352 DOI: 10.1016/j.mimet.2013.08.013]
- 57 **Bruttin A**, Brüßow H. Human volunteers receiving *Escherichia coli* phage T4 orally: a safety test of phage therapy. *Antimicrob Agents Chemother* 2005; **49**: 2874-2878 [PMID: 15980363 DOI: 10.1128/AAC.49.7.2874-2878.2005]
- 58 **Merabishvili M**, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, Lavigne R, Volckaert G, Matheus W, Verween G, De Corte P, Rose T, Jennes S, Zizi M, De Vos D, Vaneechoutte M. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. *PLoS One* 2009; **4**: e4944 [PMID: 19300511 DOI: 10.1371/journal.pone.0004944]
- 59 **McCallin S**, Alam Sarker S, Barretto C, Sultana S, Berger B, Huq S, Krause L, Bibiloni R, Schmitt B, Reuteler G, Brüßow H. Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. *Virology* 2013; **443**: 187-196 [PMID: 23755967 DOI: 10.1016/j.virol.2013.05.022]
- 60 **Sarker SA**, Sultana S, Reuteler G, Moine D, Descombes P, Charton F, Bourdin G, McCallin S, Ngom-Bru C, Neville T, Akter M, Huq S, Qadri F, Talukdar K, Kassam M, Delley M, Loiseau C, Deng Y, El Aidy S, Berger B, Brüßow H. Oral Phage Therapy of Acute Bacterial

- Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh. *EBioMedicine* 2016; **4**: 124-137 [PMID: 26981577 DOI: 10.1016/j.ebiom.2015.12.023]
- 61 **Wright A**, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant *Pseudomonas aeruginosa*; a preliminary report of efficacy. *Clin Otolaryngol* 2009; **34**: 349-357 [PMID: 19673983 DOI: 10.1111/j.1749-4486.2009.01973.x]
- 62 **Yosef I**, Manor M, Kiro R, Qimron U. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. *Proc Natl Acad Sci USA* 2015; **112**: 7267-7272 [PMID: 26060300 DOI: 10.1073/pnas.1500107112]
- 63 **Roach DR**, Donovan DM. Antimicrobial bacteriophage-derived proteins and therapeutic applications. *Bacteriophage* 2015; **5**: e1062590 [PMID: 26442196 DOI: 10.1080/21597081.2015.1062590]
- 64 **Oliveira H**, Vilas Boas D, Mesnage S, Kluskens LD, Lavigne R, Sillankorva S, Secundo F, Azeredo J. Structural and Enzymatic Characterization of ABgp46, a Novel Phage Endolysin with Broad Anti-Gram-Negative Bacterial Activity. *Front Microbiol* 2016; **7**: 208 [PMID: 26955368 DOI: 10.3389/fmicb.2016.00208]
- 65 **Lood R**, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, Euler CW, Schuch R, Fischetti VA. Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium *Acinetobacter baumannii* in a mouse bacteremia model. *Antimicrob Agents Chemother* 2015; **59**: 1983-1991 [PMID: 25605353 DOI: 10.1128/AAC.04641-14]
- 66 **Witzenrath M**, Schmeck B, Doehn JM, Tschernig T, Zahlten J, Loeffler JM, Zemlin M, Müller H, Gutbier B, Schütte H, Hippenstiel S, Fischetti VA, Suttrop N, Rosseau S. Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia. *Crit Care Med* 2009; **37**: 642-649 [PMID: 19114881 DOI: 10.1097/CCM.0b013e31819586a6]
- 67 **Schmelcher M**, Shen Y, Nelson DC, Eugster MR, Eichenseher F, Hanke DC, Loessner MJ, Dong S, Pritchard DG, Lee JC, Becker SC, Foster-Frey J, Donovan DM. Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection. *J Antimicrob Chemother* 2015; **70**: 1453-1465 [PMID: 25630640 DOI: 10.1093/jac/dku552]
- 68 **Wang Q**, Euler CW, Delaune A, Fischetti VA. Using a Novel Lysin To Help Control *Clostridium difficile* Infections. *Antimicrob Agents Chemother* 2015; **59**: 7447-7457 [PMID: 26392484 DOI: 10.1128/AAC.01357-15]
- 69 **Gilmer DB**, Schmitz JE, Euler CW, Fischetti VA. Novel bacteriophage lysin with broad lytic activity protects against mixed infection by *Streptococcus pyogenes* and methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2013; **57**: 2743-2750 [PMID: 23571534 DOI: 10.1128/AAC.02526-12]
- 70 **Shen Y**, Barros M, Vennemann T, Gallagher DT, Yin Y, Linden SB, Heselpoth RD, Spencer DJ, Donovan DM, Moulit J, Fischetti VA, Heinrich F, Lösche M, Nelson DC. A bacteriophage endolysin that eliminates intracellular streptococci. *Elife* 2016; **5**: e13152 [PMID: 26978792 DOI: 10.7554/eLife.13152]
- 71 **Yang H**, Wang DB, Dong Q, Zhang Z, Cui Z, Deng J, Yu J, Zhang XE, Wei H. Existence of separate domains in lysin PlyG for recognizing *Bacillus anthracis* spores and vegetative cells. *Antimicrob Agents Chemother* 2012; **56**: 5031-5039 [PMID: 22802245 DOI: 10.1128/AAC.00891-12]
- 72 **Keary R**, Sanz-Gaitero M, van Raaij MJ, O'Mahony J, Fenton M, McAuliffe O, Hill C, Ross RP, Coffey A. Characterization of a Bacteriophage-Derived Murein Peptidase for Elimination of Antibiotic-Resistant *Staphylococcus aureus*. *Curr Protein Pept Sci* 2016; **17**: 183-190 [PMID: 26521950]
- 73 **Yang H**, Zhang Y, Yu J, Huang Y, Zhang XE, Wei H. Novel chimeric lysin with high-level antimicrobial activity against methicillin-resistant *Staphylococcus aureus* in vitro and in vivo. *Antimicrob Agents Chemother* 2014; **58**: 536-542 [PMID: 24189265 DOI: 10.1128/AAC.01793-13]
- 74 **Diez-Martínez R**, De Paz HD, García-Fernández E, Bustamante N, Euler CW, Fischetti VA, Menéndez M, García P. A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against *Streptococcus pneumoniae*. *J Antimicrob Chemother* 2015; **70**: 1763-1773 [PMID: 25733585 DOI: 10.1093/jac/dkv038]
- 75 **Singh PK**, Donovan DM, Kumar A. Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from *Staphylococcus aureus* endophthalmitis. *Antimicrob Agents Chemother* 2014; **58**: 4621-4629 [PMID: 24890598 DOI: 10.1128/AAC.00126-14]
- 76 **Briers Y**, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, Aertsen A, Oliveira H, Azeredo J, Verween G, Pirnay JP, Miller S, Volckaert G, Lavigne R. Engineered endolysin-based "Artilysins" to combat multidrug-resistant gram-negative pathogens. *MBio* 2014; **5**: e01379-e01314 [PMID: 24987094 DOI: 10.1128/mBio.01379-14]
- 77 **Schuch R**, Lee HM, Schneider BC, Sauve KL, Law C, Khan BK, Rotolo JA, Horiuchi Y, Couto DE, Raz A, Fischetti VA, Huang DB, Nowinski RC, Wittekind M. Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant *Staphylococcus aureus*-induced murine bacteremia. *J Infect Dis* 2014; **209**: 1469-1478 [PMID: 24286983 DOI: 10.1093/infdis/jit637]
- 78 **Chopra S**, Harjai K, Chhibber S. Potential of combination therapy of endolysin MR-10 and minocycline in treating MRSA induced systemic and localized burn wound infections in mice. *Int J Med Microbiol* 2016; **306**: 707-716 [PMID: 27616281 DOI: 10.1016/j.ijmm.2016.08.003]
- 79 **Wittekind M**, Schuch R. Cell wall hydrolases and antibiotics: exploiting synergy to create efficacious new antimicrobial treatments. *Curr Opin Microbiol* 2016; **33**: 18-24 [PMID: 27257994 DOI: 10.1016/j.mib.2016.05.006]
- 80 **Granowitz EV**, Brown RB. Antibiotic adverse reactions and drug interactions. *Crit Care Clin* 2008; **24**: 421-422, xi [PMID: 18361954 DOI: 10.1016/j.ccc.2007.12.011]
- 81 **Rouveix B**. Antibiotic safety assessment. *Int J Antimicrob Agents* 2003; **21**: 215-221 [PMID: 12636981]
- 82 **Shehab N**, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. *Clin Infect Dis* 2008; **47**: 735-743 [PMID: 18694344 DOI: 10.1086/591126]
- 83 **Abedon ST**. Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages. *Pharmaceuticals* (Basel) 2015; **8**: 525-558 [PMID: 26371010 DOI: 10.3390/ph8030525]
- 84 **Górski A**, Wazna E, Dabrowska BW, Dabrowska K, Switala-Jeleń K, Miedzybrodzki R. Bacteriophage translocation. *FEMS Immunol Med Microbiol* 2006; **46**: 313-319 [PMID: 16553803 DOI: 10.1111/j.1574-695X.2006.00044.x]
- 85 **Park K**, Cha KE, Myung H. Observation of inflammatory responses in mice orally fed with bacteriophage T7. *J Appl Microbiol* 2014; **117**: 627-633 [PMID: 24916438 DOI: 10.1111/jam.12565]
- 86 **Borysowski J**, Górski A. Is phage therapy acceptable in the immunocompromised host? *Int J Infect Dis* 2008; **12**: 466-471 [PMID: 18400541 DOI: 10.1016/j.ijid.2008.01.006]
- 87 **Tetz G**, Tetz V. Bacteriophage infections of microbiota can lead to leaky gut in an experimental rodent model. *Gut Pathog* 2016; **8**: 33 [PMID: 27340433 DOI: 10.1186/s13099-016-0109-1]
- 88 **Hong Y**, Thimmapuram J, Zhang J, Collings CK, Bhide K, Schmidt K, Ebner PD. The impact of orally administered phages on host immune response and surrounding microbial communities. *Bacteriophage* 2016; **6**: e1211066 [PMID: 27738553 DOI: 10.1080/21597081.2016.1211066]
- 89 **Pincus NB**, Reckhow JD, Saleem D, Jammeh ML, Datta SK, Myles IA. Strain Specific Phage Treatment for *Staphylococcus aureus* Infection Is Influenced by Host Immunity and Site of Infection. *PLoS One* 2015; **10**: e0124280 [PMID: 25909449 DOI: 10.1371/journal.pone.0124280]
- 90 **Rea K**, Dinan TG, Cryan JF. The microbiome: A key regulator of stress and neuroinflammation. *Neurobiol Stress* 2016; **4**: 23-33 [PMID: 27981187 DOI: 10.1016/j.ynstr.2016.03.001]
- 91 **Metsälä J**, Lundqvist A, Virta LJ, Kaila M, Gissler M, Virtanen SM. Prenatal and post-natal exposure to antibiotics and risk of asthma in childhood. *Clin Exp Allergy* 2015; **45**: 137-145 [PMID: 24943808 DOI: 10.1111/cea.12356]
- 92 **Cox LM**, Blaser MJ. Antibiotics in early life and obesity. *Nat Rev Endocrinol* 2015; **11**: 182-190 [PMID: 25488483 DOI: 10.1038/nrendo.2014.210]
- 93 **Mikkelsen KH**, Allin KH, Knop FK. Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review

- of the literature. *Diabetes Obes Metab* 2016; **18**: 444-453 [PMID: 26818734 DOI: 10.1111/dom.12637]
- 94 **Mai V**, Ukhanova M, Reinhard MK, Li M, Sulakvelidze A. Bacteriophage administration significantly reduces *Shigella* colonization and shedding by *Shigella*-challenged mice without deleterious side effects and distortions in the gut microbiota. *Bacteriophage* 2015; **5**: e1088124 [PMID: 26909243 DOI: 10.1080/21597081.2015.1088124]
- 95 **Galtier M**, De Sordi L, Maura D, Arachchi H, Volant S, Dillies MA, Debarbieux L. Bacteriophages to reduce gut carriage of antibiotic resistant uropathogens with low impact on microbiota composition. *Environ Microbiol* 2016; **18**: 2237-2245 [PMID: 26971586 DOI: 10.1111/1462-2920.13284]
- 96 **Servick K**. Drug development. Beleaguered phage therapy trial presses on. *Science* 2016; **352**: 1506 [PMID: 27339963 DOI: 10.1126/science.352.6293.1506]
- 97 **Koskella B**. Bacteria-phage interactions across time and space: merging local adaptation and time-shift experiments to understand phage evolution. *Am Nat* 2014; **184** Suppl 1: S9-S21 [PMID: 25061680 DOI: 10.1086/676888]
- 98 **Niu YD**, Johnson RP, Xu Y, McAllister TA, Sharma R, Louie M, Stanford K. Host range and lytic capability of four bacteriophages against bovine and clinical human isolates of Shiga toxin-producing *Escherichia coli* O157: H7. *J Appl Microbiol* 2009; **107**: 646-656 [PMID: 19302306 DOI: 10.1111/j.1365-2672.2009.04231.x]
- 99 **Latz S**, Wahida A, Arif A, Häfner H, Hoß M, Ritter K, Horz HP. Preliminary survey of local bacteriophages with lytic activity against multi-drug resistant bacteria. *J Basic Microbiol* 2016; **56**: 1117-1123 [PMID: 27194637 DOI: 10.1002/jobm.201600108]
- 100 **Costerton JW**. Introduction to biofilm. *Int J Antimicrob Agents* 1999; **11**: 217-221; discussion 237-239 [PMID: 10394973]
- 101 **Hughes KA**, Sutherland IW, Jones MV. Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase. *Microbiology* 1998; **144** (Pt 11): 3039-3047 [PMID: 9846739 DOI: 10.1099/00221287-144-11-3039]
- 102 **Anwar H**, Strap JL, Chen K, Costerton JW. Dynamic interactions of biofilms of mucoid *Pseudomonas aeruginosa* with tobramycin and piperacillin. *Antimicrob Agents Chemother* 1992; **36**: 1208-1214 [PMID: 1416820]
- 103 **Amorena B**, Gracia E, Monzón M, Leiva J, Oteiza C, Pérez M, Alabart JL, Hernández-Yago J. Antibiotic susceptibility assay for *Staphylococcus aureus* in biofilms developed in vitro. *J Antimicrob Chemother* 1999; **44**: 43-55 [PMID: 10459809]
- 104 **Gabisoniya TG**, Loladze MZ, Nadiradze MM, Chakhunashvili NK, Alibegashvili MG, Tamarashvili NG, Pushkina VA. Effects of bacteriophages on biofilm formation by strains of *Pseudomonas aeruginosa*. *Appl Biochem Microbiol* 2016; **52**: 293-297 [DOI: 10.1134/S0003683816030042]
- 105 **Chan BK**, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. *Future Microbiol* 2013; **8**: 769-783 [PMID: 23701332 DOI: 10.2217/fmb.13.47]
- 106 **Regeimbal JM**, Jacobs AC, Corey BW, Henry MS, Thompson MG, Pavlicek RL, Quinones J, Hannah RM, Ghebremedhin M, Crane NJ, Zurawski DV, Teneza-Mora NC, Biswas B, Hall ER. Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from *Acinetobacter baumannii* Wound Infections. *Antimicrob Agents Chemother* 2016; **60**: 5806-5816 [PMID: 27431214 DOI: 10.1128/AAC.02877-15]
- 107 **Calero-Cáceres W**, Muniesa M. Persistence of naturally occurring antibiotic resistance genes in the bacteria and bacteriophage fractions of wastewater. *Water Res* 2016; **95**: 11-18 [PMID: 26978717 DOI: 10.1016/j.watres.2016.03.006]
- 108 **Sheth RU**, Cabral V, Chen SP, Wang HH. Manipulating Bacterial Communities by in situ Microbiome Engineering. *Trends Genet* 2016; **32**: 189-200 [PMID: 26916078 DOI: 10.1016/j.tig.2016.01.005]

P- Reviewer: Actis GC, Lizarraga I, Sava G **S- Editor:** Ji FF
L- Editor: A **E- Editor:** Lu YJ





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

